Trailblazers: Helping Make Cell Therapies Less Expensive & More Available

Automating cell therapy manufacturing is critical to bridging the gap between clinical innovation and commercial scalability.

In this episode of Trailblazers, Life Science Connect's Perry Rearick talks with Jerry Jang, Vice President of Global Sales at Cellbri, about how Cellbri is bringing customizable automation to cell therapy manufacturing. Traditional cell therapy development is highly complex and manual, resulting in labor shortages, elevated costs, and regulatory challenges when scaling up production. Rather than forcing developers to adapt their biological processes to fit rigid automation systems, which can alter critical quality attributes and derail regulatory filings, Cellbri's flexible hardware templates and modular software allow for collaboration with developers to engineer an automated operation while preserving essential cell biology. Discover more about Cellbri's work to make advanced cell therapies more affordable and accessible to patients.